公开(公告)号：US20220357312A1

公开(公告)日：2022-11-10

申请号：US17766038

申请日：2020-10-02

申请人： Takeda Vaccines, Inc.

发明人： Isamu TSUJI ,  Hansi DEAN ,  Michael EGAN

IPC分类号： G01N33/50 ,  C07K16/10 ,  C12N7/00 ,  C07K14/005

摘要： The present invention relates to methods for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture specific for a virus using virus-like particles (VLPs) and/or live viruses or inactivated viruses attached to biosensors. Further, the present invention relates to the VLPs and live or inactivated viruses attached to biosensors and methods for producing them.

公开(公告)号：US20240142451A1

公开(公告)日：2024-05-02

申请号：US18284987

申请日：2022-03-31

申请人： TAKEDA VACCINES, INC.

发明人： Isamu TSUJI ,  Hansi DEAN ,  Mayuri SHARMA ,  Christina DEMASO ,  Michael EGAN ,  Eduardo NASCIMENTO

IPC分类号： G01N33/569 ,  G01N33/543

CPC分类号： G01N33/56983 ,  G01N33/54373 ,  G01N2333/185 ,  G01N2469/20 ,  G01N2470/04

摘要： The present invention relates to a method for characterizing the immune response of a subject to a tetravalent dengue virus composition by performing the method for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture and at least one other method. In a further embodiment, the present invention relates to a method for characterizing the immune response of a subject to a virus-containing vaccine composition by performing a combination of assays. In a further embodiment, the present invention relates to a method for predicting protective efficacy of a dengue vaccine candidate. In another embodiment the present invention relates to a method for preparing a vaccine formulation.

公开(公告)号：US20220332800A1

公开(公告)日：2022-10-20

申请号：US17295770

申请日：2019-09-20

申请人： Takeda Vaccines, Inc.

发明人： Subash C. DAS ,  Isamu TSUJI ,  Jill A. LIVENGOOD ,  Hansi DEAN

IPC分类号： C07K16/10 ,  A61K39/42 ,  A61K45/06 ,  G01N33/569

摘要： The present invention provides isolated monoclonal antibodies, or antigen-binding portions thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies, or antigen-binding portions thereof, according to the present invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. The antibodies, or antigen-binding portions thereof, according to the present invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.